Erdafitinib Granted Full Approval for Bladder Cancer
The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug Administration (FDA) has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced...